| formoterol fumarate (PT005) / AstraZeneca |
NCT00139932: Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) |
|
|
| Completed | 4 | 255 | NA | formoterol fumarate | Merck Sharp & Dohme LLC, Integrated Therapeutics Group, Novartis | Pulmonary Disease, Chronic Obstructive | 11/06 | 11/06 | | |
NCT00633776: Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) |
|
|
| Withdrawn | 4 | 0 | US | formoterol fumarate, Perforomist (nebulized formoterol fumarate), Foradil (aerosolizer dry powder formoterol fumarate) | University of California, Los Angeles, Dey, L.P. | Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema | 01/09 | 01/09 | | |
| Completed | 4 | 311 | US | Budesonide / formoterol fumarate (SYMBICORT), SYMBICORT, Budesonide, PULMICORT | AstraZeneca | Asthma | 09/09 | 09/09 | | |
| Completed | 4 | 431 | Europe | FOSTER, Seretide | Chiesi Farmaceutici S.p.A. | Asthmatic Patients | 09/10 | 12/10 | | |
NCT01712854: Effects of Symbicort on the Ventilatory Kinematics |
|
|
| Terminated | 4 | 9 | US | Budesonide, Symbicort | Columbia University, AstraZeneca | Chronic Obstructive Lung Disease | 09/12 | 09/12 | | |
SANOB, NCT01853787: Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - Study |
|
|
| Completed | 4 | 49 | Europe | Formoterol Fumarate, Foradil spray, Novartis Farma S.p.A., Salmeterol, Serevent, GlaxoSmithKline S.p.A. | University of Milan, Fondazione Salvatore Maugeri, Università degli Studi di Ferrara | Chronic Obstructive Pulmonary Disease (COPD) | 06/15 | 06/15 | | |
2008-005707-26: Effect of beclomethasone dipropionate/formoterol fumarate (BDP+FF) administered as a fixed pMDI combination on lung impedance and exhaled nitric oxide in comparison with the fixed combination of budesonide and formoterol fumarate (Symbicort Turbohaler®). FLEX study (Foster fixed combination on Lung Impedance and Exhaled nitric oXide)A single-centre, randomized, double blind, double-dummy, two-way cross-over, repeated dose study |
|
|
| Completed | 4 | 24 | Europe | Foster® 100/6, SYMBICORT® TURBOHALER® 160/4,5, CHF 1535 HFA pMDI, NA, FOSTER®, Symbicort® Turbohaler®, FOSTER®, Symbicort® Turbohaler® | Chiesi Farmaceutici SpA | Bronchial Asthma | | 05/10 | | |
2008-002844-40: A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENTS FORMOTEROL FUMARATE AND BECLOMETHASONE DIPROPIONATE VIA pMDI WITH HFA-134A PROPELLANT, WHEN GIVEN AFTER INHALED ALLERGEN CHALLENGE IN ASTHMATIC PATIENTS |
|
|
| Ongoing | 4 | 20 | Europe | CHF 718 HFA, CHF 718 HFA, Atimos, Foster, Atimos, Foster | Leiden University Medical Center | astma | | | | |
NCT01488019: Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) |
|
|
| Completed | 4 | 1071 | US | Perforomist-Placebo, Perforomist, Perforomist, nebulization, COPD, Formoterol fumarate | Dey | COPD | 01/16 | 01/16 | | |
| Terminated | 4 | 827 | US | Formoterol 12 mcg, FOR258, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg, Fluticasone propionate 500 mcg, Placebo | Novartis Pharmaceuticals | Persistent Asthma | 05/16 | 05/16 | | |
| Completed | 4 | 267 | Canada, Europe | Aclidinium/Formoterol, Placebo | AstraZeneca, Menarini Group | Pulmonary Disease, Chronic Obstructive | 07/16 | 07/16 | | |
NCT02533505: Phase IV O2 Consumption Study in COPD Patients. |
|
|
| Completed | 4 | 51 | US | Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol, Matching Placebo pMDI 160/4.5 μg | AstraZeneca | Chronic Obstructive Pulmonary Disease (COPD) | 08/16 | 08/16 | | |
NCT02045875: Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence |
|
|
| Completed | 4 | 50 | US | Dulera, mometasone furoate/formoterol fumarate dihydrate | Asthma Management Systems, Merck Sharp & Dohme LLC, West Penn Allegheny Health System | Asthma | 07/17 | 07/17 | | |
ASTUTE, NCT03181880: To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease |
|
|
| Withdrawn | 4 | 0 | NA | Aclidinium bromide/formoterol fumarate combination, Duaklir™ Genuair®, Standard of Care | AstraZeneca, QuintilesIMS, Inc. | Chronic Obstructive Pulmonary Disease | 12/18 | 12/18 | | |
